InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Lyell Immunopharma, Inc.

LYEL Clue Score29
United States Fiscal year ends December CIK 0001806952 Results filed 4 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

10
Insider
Date
Role
Action
Shares
Price
Amount
ARCH Venture Fund XIII, L.P.
4 Nov 2026
10% owner
Buy indirect
2,321,262
$10.77
$25.00M
ARCH Venture Partners IX, LLC
4 Nov 2026
10% owner
Buy indirect
2,321,262
$10.77
$25.00M
ARCH Venture Fund XIII, L.P.
6 Mar 2026
10% owner
Buy indirect
488,090
$25.61
$12.50M
ARCH Venture Partners IX, LLC
6 Mar 2026
10% owner
Buy indirect
488,090
$25.61
$12.50M
Otis W Brawley
31 Mar 2025
Director
Buy
35,640
$0.56
$19.96K
Sumant Ramachandra
21 Mar 2025
Director
Buy indirect
200,000
$0.58
$115.22K
Charles W. Newton
17 Mar 2025
Chief Financial Officer
Buy indirect
200,000
$0.56
$111.62K
Lynn Seely
14 Mar 2025
President and CEO
Buy
175,000
$0.61
$106.19K
Richard Klausner
14 Mar 2025
Director
Buy indirect
158,000
$0.60
$94.94K
Cathy Friedman
21 Jun 2021
Director
Buy indirect
17,648
$17.00
$300.02K
Show all 55 transactions →

What was left out

Form 4 filings counted 142
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 41
Transactions with no price 0
Shares from compensation/vesting 117,785,633
Sales filed before the plan box existed 1
History held since 23 Jun 2021